Compare ASTL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | ADCT |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 484.4M |
| IPO Year | N/A | 2019 |
| Metric | ASTL | ADCT |
|---|---|---|
| Price | $3.39 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.4M | 903.2K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | $1.15 |
| Revenue Next Year | $33.17 | $86.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $3.02 | $1.05 |
| 52 Week High | $7.25 | $4.98 |
| Indicator | ASTL | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 29.96 | 48.68 |
| Support Level | $3.09 | $3.79 |
| Resistance Level | $4.77 | $4.63 |
| Average True Range (ATR) | 0.28 | 0.31 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 0.69 | 17.79 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).